Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Improving glycaemic outcomes in uncontrolled
high risk type 2 diabetes:

The practicalities of using Suliqua®(insulin
glargine 100 units/mL and lixisenatide) – why now?

Countdown to the next webinar

Taking place on 5 May 2021

13:00 and 19:00

Days
Hours
Minutes
Seconds

Thanks for registering

Prescribing information for Suliqua (insulin glargine 100 units/mL and lixisenatide) can be accessed by clicking here.

This promotional webinar was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Sanofi Tel: 0800 0902314. Alternatively, send via email to UK-drugsafety@sanofi.com

Job code: MAT-GB-2005380 (v1.0) | Date of preparation: March 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.